Levine Cancer shared a post on X:
“Survivors are living longer thanks to new anticancer therapies, so the Overall Survival endpoint is a critical focus of oncology trials.
Dr. Ruben Mesa worked at Clinical Cancer Research and the American Association for Cancer Research on a paper detailing how to keep up the pace of timely drug development.
